{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:51:36Z","timestamp":1767135096143,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd008661","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000}}],"reference-count":152,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008661.pub2","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T23:56:35Z","timestamp":1576108595000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Modafinil for people with schizophrenia or related disorders"],"prefix":"10.1002","author":[{"given":"Javier","family":"Ortiz-Orendain","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology; Mayo Clinic; Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio A","family":"Covarrubias-Castillo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; Hospital Civil de Guadalajara \"Fray Antonio Alcalde\"; Guadalajara Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan Omar","family":"Vazquez-Alvarez","sequence":"additional","affiliation":[{"name":"Institute of Experimental and Clinical Therapeutics, Department of Physiology; Health Sciences University Center, University of Guadalajara; Guadalajara Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Castiello-de Obeso","sequence":"additional","affiliation":[{"name":"Psychophysiology Laboratory; Western Institute of Technology and Higher Education (ITESO); Guadalajara Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo E","family":"Arias Qui\u00f1ones","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery. Hospital Civil \"Fray Antonio Alcalde\"; University of Guadalajara; Guadalajara Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Seegers","sequence":"additional","affiliation":[{"name":"Medical School for International Health; Ben Gurion University; New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Enrique","family":"Colunga-Lozano","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact; McMaster University; Hamilton Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD008661.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00213-011-2513-z","article-title":"A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia","volume":"220","author":"Arbabi","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Freudenreich O Henderson DC Macklin EA Evins AE Fan X Cather C Modafinil for clozapine-treated schizophrenia patients. a double-blind, placebo-controlled trial 12th International Congress on Schizophrenia Research; 2009 Mar 28-Apr 1; California (CA) San Diego (CA) Oxford University Press 2009 358","DOI":"10.4088\/JCP.08m04683"},{"issue":"12","key":"10.1002\/14651858.CD008661.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.4088\/JCP.08m04683","article-title":"Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial","volume":"70","author":"Freudenreich","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD008661.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.schres.2011.04.009","article-title":"Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia","volume":"130","author":"Henderson","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0005|cit5","unstructured":"A placebo-controlled trial of modafinil (Provigil) added to clozapine in patients with schizophrenia http:\/\/www.clinicaltrials.gov 2007"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0006|cit6","unstructured":"Kumar S Tharyan P Thomas N Adams CE Modafinil for clozapine induced adverse effects in people with schizophrenia and schizoaffective disorder in remission: a randomized, placebo-controlled trial stopped early for harms 8th Winter Symposium on Evidence Informed Healthcare; 2010 Jan 11-14; Vellore, India Vellore, India 2010"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0007|cit7","unstructured":"Neuroimaging effects of a single dose of modafinil on brain activation in patients with schizophrenia: a randomised controlled trial http:\/\/isrctn.org\/ISRCTN66900787 2013"},{"issue":"13","key":"10.1002\/14651858.CD008661.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1017\/S0033291717000885","article-title":"Modafinil and cognitive enhancement in schizophrenia and healthy volunteers: the effects of test battery in a randomised controlled trial","volume":"47","author":"Lees","year":"2017","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0009|cit9","first-page":"A309","article-title":"Modafinil as an adjunctive treatment strengthened circadian activity rhythms in schizophrenia","volume":"36","author":"Liu","year":"2013","journal-title":"Sleep"},{"issue":"1","key":"10.1002\/14651858.CD008661.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.schres.2013.07.039","article-title":"Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study","volume":"150","author":"Lohr","year":"2013","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0011|cit11","unstructured":"Modafinil augmentation therapy for excessive daytime sleepiness and negative symptoms in patients with schizophrenia http:\/\/www.clinicaltrials.gov 2007"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0012|cit12","unstructured":"A pilot study of cognitive enhancer and cognitive training combination: testing a therapeutic paradigm for cognitive impairment in schizophrenia http:\/\/www.controlled-trials.com 2010"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008661.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/S0920-9964(14)70625-5","article-title":"The effects of modafinil on cognitive training: a proof-of-concept trial in patients with schizophrenia","volume":"153","author":"Michalopoulou","year":"2014","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Michalopoulou PG Lewis SW Drake R Reichenberg A Emsley R Kalpakidou AK The effects of a combined intervention for cognition in schizophrenia on COGSTATE schizophrenia battery European Psychiatry 2015 30 255 23291","DOI":"10.1016\/S0924-9338(15)30210-8"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Michalopoulou PG Lewis SW Drake RJ Reichenberg A Emsley R Kalpakidou AK Modafinil combined with cognitive training: pharmacological augmentation of cognitive training in schizophrenia European Neuropsychopharmacology 2015 28 1178 89 22066","DOI":"10.1016\/j.euroneuro.2015.03.009"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0016|cit16","first-page":"S324","article-title":"The effects of a single dose of modafinil on MATRICS Consensus Cognitive Battery performance in chronic schizophrenia","volume":"41","author":"Michalopoulou","year":"2015","journal-title":"Schizophrenia Bulletin"},{"issue":"S1","key":"10.1002\/14651858.CD008661.pub2-BIB0017|cit17","first-page":"S36","article-title":"The effects of modafinil and cognitive training on cognitive performance","volume":"38","author":"Reichenberg","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008661.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1017\/CBO9780511666971.017","article-title":"Modafinil: a candidate for pharmacotherapy of negative symptoms in schizophrenia","volume":"3","author":"Peloian","year":"2008","journal-title":"Progress in Neurotherapeutics and Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0019|cit19","first-page":"501","article-title":"A double-blind placebo controlled trial of modafinil for negative symptoms in schizophrenia","volume":"31","author":"Pierre","year":"2005","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0020|cit20","unstructured":"Pierre J Modafinil for schizophrenia Stanley Foundation Research Programs 2009"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008661.pub2-BIB0021|cit21","first-page":"S207","article-title":"A double-blind placebo controlled trial of modafinil for negative symptoms in schizophrenia","volume":"30","author":"Pierre","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD008661.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4088\/JCP.v68n0507","article-title":"A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia","volume":"68","author":"Pierre","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Prasuna PL Sudhakar TP Impact of modafinil add-on with atypical anti-psychotics on excessive daytime drowsiness Indian Journal of Psychological Medicine 2015 37 4 388 92 23742","DOI":"10.4103\/0253-7176.168561"},{"issue":"2","key":"10.1002\/14651858.CD008661.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4103\/0253-7176.130982","article-title":"A placebo controlled trial on add-on modafinil on the anti-psychotic treatment emergent hyperglycemia and hyperlipidemia","volume":"36","author":"Prasuna","year":"2014","journal-title":"Indian Journal of Psychological Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008661.pub2-BIB0025|cit25","first-page":"24","article-title":"Study of effects of modafinil add-on therapy on excessive day time drowsiness and weight gain in patients on atypical antipsychotics","volume":"30","author":"Sudhakar","year":"2008","journal-title":"Indian Journal of Psychological Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008661.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.4088\/JCP.v66n0705","article-title":"Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications","volume":"66","author":"Sevy","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"Shafti SS Akbari S Intractability of deficit syndrome of schizophrenia against adjunctive modafinil Journal of Clinical Psychopharmacology 2016 36 1 45 9 23753","DOI":"10.1097\/JCP.0000000000000437"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1192\/bjp.bp.105.017335","article-title":"Modafinil and unconstrained motor activity in schizophrenia: double-blind crossover placebo-controlled trial","volume":"189","author":"Farrow","year":"2006","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008661.pub2-BIB0029|cit29","first-page":"144","article-title":"Modafinil modulates prefrontal function in schizophrenia","volume":"67","author":"Green","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0030|cit30","first-page":"511","article-title":"Effects of modafinil on prefrontal function and voluntary behaviour in chronic schizophrenia","volume":"31","author":"Hunter","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"12","key":"10.1002\/14651858.CD008661.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1176\/ajp.2006.163.12.2184","article-title":"Impact of modafinil on prefrontal executive function in schizophrenia","volume":"163","author":"Hunter","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0032|cit32","unstructured":"Acute effects of modafinil on cognitive function and activation of prefrontal cortex in people with schizophrenia http:\/\/www.isrctn.com\/ISRCTN54567688 2003"},{"issue":"1","key":"10.1002\/14651858.CD008661.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1192\/bjp.187.1.55","article-title":"Modafinil modulates anterior cingulate function in chronic schizophrenia","volume":"187","author":"Spence","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0034|cit34","unstructured":"Kane JM D'Souza DC Patkar AA Youakim J Tiller J Yang R Efficacy and tolerability of adjunctive armodafinil in patients with schizophrenia International Congress on Schizophrenia Research; 2009 Mar 28 - Apr 1; San Diego, California, USA 2009"},{"issue":"11","key":"10.1002\/14651858.CD008661.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.4088\/JCP.09m05950gry","article-title":"Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: A 4-week, double-blind, placebo-controlled study","volume":"71","author":"Kane","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0036|cit36","unstructured":"Kane JM D'Souza DC Patkar AA Yuakim J Tiller J Yang R Effects of adjunctive armodafinil in schizophrenia American College of Neuropsychopharmacology Annual Meeting; 2008 Oct 1-11; Scottsdale, Arizona 2008"},{"issue":"3","key":"10.1002\/14651858.CD008661.pub2-BIB0037|cit37","first-page":"336","article-title":"Effects of adjunctive armodafinil on patients with schizophrenia","volume":"11","author":"Tiller","year":"2009","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008661.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0920-9964(06)70392-9","article-title":"The impact of modafinil as an adjunct to a second generation antipsychotic on cognitive functioning in patients with first psychotic episode","volume":"86","author":"Leblanc","year":"2006","journal-title":"Schizophrenia Research"},{"key":"#cr-split#-10.1002\/14651858.CD008661.pub2-BIB0039|cit39.1","unstructured":"San Diego, CA San Diego (CA) Oxford Univ Press 2009 283"},{"key":"#cr-split#-10.1002\/14651858.CD008661.pub2-BIB0039|cit39.2","unstructured":"Letourneau K Demers MF Simard M Emond C Roy MA A 10-week, double-blind, placebo controlled, cross-over trial of adjunctive modafinil for neurocognitive impairments in schizophrenia 12th International Congress on Schizophrenia Research; 2009 Mar 28-Apr 1; San Diego, CA San Diego"},{"key":"#cr-split#-10.1002\/14651858.CD008661.pub2-BIB0039|cit39.3","unstructured":"(CA) Oxford Univ Press 2009 283"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0040|cit40","unstructured":"The impact of modafinil as an adjunctive to a second generation antipsychotic on cognitive functioning in schizophrenia and schizophrenia spectrum psychosis http:\/\/www.clinicaltrials.gov 2006"},{"issue":"2","key":"10.1002\/14651858.CD008661.pub2-BIB0041|cit41","first-page":"379","article-title":"Modafinil effects on cognitive control in schizophrenia: a double-blind, placebo-controlled single-dose pharmaco-FMRI study","volume":"33","author":"Minzenberg","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD008661.pub2-BIB0042|cit42","first-page":"S48","article-title":"Modafinil effects on cognition in schizophrenia: a dose-ranging study","volume":"3","author":"Minzenberg","year":"2010","journal-title":"Clinical and Translational Science"},{"issue":"9","key":"10.1002\/14651858.CD008661.pub2-BIB0043|cit43","first-page":"87","article-title":"Dose-response effects of single-dose modafinil on cognition in schizophrenia","volume":"67","author":"Minzenberg","year":"2010","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0044|cit44","unstructured":"A dose-response study of modafinil effects on cognition in healthy adults and in schizophrenia patients http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0045|cit45","first-page":"S282","article-title":"Subcortical\/cortical effects of single-dose modafinil during cognitive control performance in schizophrenia","volume":"35","author":"Minzenberg","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0046|cit46","unstructured":"Minzenberg M Yoon J Nunez del Prado J Soosman S Carter C Subcortical\/cortical effects of single-dose modafinil during cognitive control performance in schizophrenia 49th Annual meeting of the American College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida 2010"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008661.pub2-BIB0047|cit47","first-page":"282","article-title":"Modafinil effects on locus coeruleus and ventral tegmental area during cognitive control performance in schizophrenia","volume":"9","author":"Minzenberg","year":"2011","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0048|cit48","first-page":"290","article-title":"Subcortical\/cortical effects of modafinil during cognitive control in schizophrenia","volume":"37","author":"Minzenberg","year":"2011","journal-title":"Schizophrenia Bulletin"},{"issue":"S1","key":"10.1002\/14651858.CD008661.pub2-BIB0049|cit49","first-page":"S433","article-title":"Modafinil modulates activation and functional coupling of the prefrontal cortex during working memory in patients with schizophrenia","volume":"38","author":"Apud","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0050|cit50","unstructured":"Randomized, double-blinded, placebo controlled study of the effects of modafinil on cognitive function in patients with schizophrenia and normal controls based on COMT genotype http:\/\/www.clinicaltrials.gov 2006"},{"issue":"1-3","key":"10.1002\/14651858.CD008661.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.schres.2011.05.015","article-title":"The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia\/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial","volume":"130","author":"Bobo","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0052|cit52","unstructured":"Effects of modafinil on the tolerability and efficacy for cognition of atypical antipsychotic drugs in patients with schizophrenia or schizoaffective disorder http:\/\/www.clinicaltrials.gov 2006"},{"issue":"13","key":"10.1002\/14651858.CD008661.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1038\/npp.2014.155","article-title":"Modafinil effects on middle-frequency oscillatory power during rule selection in schizophrenia","volume":"39","author":"Minzenberg","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Minzenberg MJ Yoon JH Cheng Y Carter CS Sustained modafinil treatment effects on control-related gamma oscillatory power in schizophrenia Neuropsychopharmacology 2016 41 5 1231 40 25855","DOI":"10.1038\/npp.2015.271"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0055|cit55","unstructured":"Modafinil for treatment of cognitive dysfunction in schizophrenia http:\/\/www.clinicaltrials.gov 2007"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0056|cit56","unstructured":"A 4-week, double-blind, placebo-controlled, parallel-group, fixed-dosage study to evaluate the efficacy and safety of armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia http:\/\/www.clinicaltrials.gov 2007"},{"issue":"1-3","key":"10.1002\/14651858.CD008661.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2011.11.006","article-title":"Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study","volume":"135","author":"Kane","year":"2012","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0058|cit58","first-page":"307","article-title":"Adjunctive armodafinil for negative symptoms in patients with schizophrenia: a double-blind, placebo-controlled study","volume":"37","author":"Kane","year":"2011","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0059|cit59","unstructured":"Study to evaluate the efficacy and safety of armodafinil as adjunctive therapy in adults with schizophrenia http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0060|cit60","first-page":"319","article-title":"Cognitive enhancing drugs in preclinical models of schizophrenia and improvements in cognition by modafinil in patients with chronic and first episode schizophrenia","volume":"37","author":"Sahakian","year":"2011","journal-title":"Schizophrenia Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD008661.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.biopsych.2010.09.043","article-title":"Effects of modafinil on emotional processing in first episode psychosis","volume":"69","author":"Scoriels","year":"2011","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008661.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00213-011-2472-4","article-title":"Effects of modafinil on cognitive functions in first episode psychosis","volume":"220","author":"Scoriels","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0063|cit63","unstructured":"Sahakian BJ Study of the cognitive effects of modafinil in schizophrenia National Research Register 2002 4"},{"issue":"7","key":"10.1002\/14651858.CD008661.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/sj.npp.1300457","article-title":"Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia","volume":"29","author":"Turner","year":"2004","journal-title":"Neuropyschopharmacology"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1017\/CBO9780511663529.013","volume-title":"Progress in Neurotherapeutics and Neuropsychopharmacology","author":"Turner","year":"2006"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD008661.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00213-010-1839-2","article-title":"Dopamine transporter-related effects of modafinil in rhesus monkeys","volume":"210","author":"Andersen","year":"2010","journal-title":"Psychopharmacology"},{"issue":"60","key":"10.1002\/14651858.CD008661.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jpsychires.2014.09.013","article-title":"Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Andrade","year":"2015","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0069|cit69","volume-title":"The Scale for the Assessment of Negative Symptoms (SANS)","author":"Andreasen","year":"1983"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0070|cit70","volume-title":"The Scale for the Assessment of Positive Symptoms (SAPS)","author":"Andreasen","year":"1984"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0071|cit71","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"issue":"5","key":"10.1002\/14651858.CD008661.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0278-5846(88)90014-0","article-title":"Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil","volume":"12","author":"Bastoji","year":"1988","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD008661.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.euroneuro.2015.07.028","article-title":"Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review","volume":"25","author":"Battleday","year":"2015","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0074|cit74","volume-title":"Multilingual Aphasia Examination","author":"Benton","year":"1989"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD008661.pub2-BIB0076|cit76","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"6","key":"10.1002\/14651858.CD008661.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/sleep\/27.6.1181","article-title":"What keeps us awake: the neuropharmacology of stimulants and wakefulness promoting medications","volume":"27","author":"Boutrel","year":"2004","journal-title":"Sleep"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Buchanan","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0165-1781(89)90188-1","article-title":"The Continuous Performance Test, Identical Pairs Version: II. Contrasting attentional profiles in schizophrenic and depressed patients","volume":"29","author":"Cornblatt","year":"1988","journal-title":"Psychiatry Research"},{"issue":"3","key":"10.1002\/14651858.CD008661.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/schbul\/sbq090","article-title":"Modafinil reverses phencyclidine-induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivity","volume":"38","author":"Dawson","year":"2010","journal-title":"Schizophrenia Bulletin"},{"issue":"16","key":"10.1002\/14651858.CD008661.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1097\/00001756-200111160-00032","article-title":"Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats","volume":"12","author":"Saint Hilaire","year":"2001","journal-title":"Neuroreport"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0082|cit82","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0083|cit83","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0086|cit86","first-page":"170","volume-title":"Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies","author":"Dupuy","year":"1984"},{"issue":"1-2","key":"10.1002\/14651858.CD008661.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0014-2999(79)90033-5","article-title":"A possible \u03b1-adrenergic mechanism for drug (CRL 40028)-induced hyperactivity","volume":"59","author":"Duteil","year":"1979","journal-title":"European Journal of Pharmacology"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD008661.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD008661.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0304-3940(97)00962-2","article-title":"Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil","volume":"241","author":"Engber","year":"1998","journal-title":"Neuroscience Letters"},{"issue":"4","key":"10.1002\/14651858.CD008661.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/syn.20111","article-title":"Modafinil enhances the increase of extracellular serotonin levels induced by the antidepressant drugs fluoxetine and imipramine: a dual probe microdialysis study in awake rat","volume":"55","author":"Ferraro","year":"2005","journal-title":"Synapse"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0092|cit92","doi-asserted-by":"crossref","unstructured":"Furukawa TA Guyatt GH Griffith LE Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses [see comment] International Journal of Epidemiology 2002 31 1 72 6","DOI":"10.1093\/ije\/31.1.72"},{"issue":"7","key":"10.1002\/14651858.CD008661.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD008661.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/npp.2010.233","article-title":"Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals","volume":"36","author":"Ghahremani","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0095|cit95","first-page":"373","volume-title":"Handbook of Physiology: The Nervous System V","volume":"5","author":"Goldman-Rakic","year":"1987"},{"issue":"3","key":"10.1002\/14651858.CD008661.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/npp.2011.260","article-title":"Modulation of fronto-cortical activity by modafinil: a functional imaging and fos study in the rat","volume":"37","author":"Gozzi","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0098|cit98","volume-title":"Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0100|cit100","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008 Available from handbook.cochrane.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0101|cit101","unstructured":"Higgins JPT Deeks JJ Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0102|cit102","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/1097-4679(196501)21:1<65::AID-JCLP2270210122>3.0.CO;2-I","article-title":"Nurses' observation scale for inpatient evaluation: a new scale for measuring improvement in chronic schizophrenia","volume":"21","author":"Honigfeld","year":"1965","journal-title":"Journal of Clinical Psychology"},{"issue":"3","key":"10.1002\/14651858.CD008661.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III - the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1176\/ajp.2006.163.12.2184","article-title":"Impact of modafinil on prefrontal executive function in schizophrenia","volume":"163","author":"Hunter","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008661.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD008661.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","article-title":"A systematic review and meta-analysis of recovery in schizophrenia","volume":"39","author":"J\u00e4\u00e4skel\u00e4inen","year":"2012","journal-title":"Schizophrenia Bulletin"},{"issue":"10","key":"10.1002\/14651858.CD008661.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2013.155","article-title":"Schizophrenia is a cognitive illness: time for a change in focus","volume":"70","author":"Kahn","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0109|cit109","doi-asserted-by":"crossref","unstructured":"Kay SR Opler LA Fiszbein A Positive and Negative Syndrome Scale (PANSS) Manual North Tonawanda, NY Multi-Health Systems 1986","DOI":"10.1093\/schbul\/13.2.261"},{"issue":"2","key":"10.1002\/14651858.CD008661.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD008661.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/0022-3956(94)90009-4","article-title":"Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited","volume":"28","author":"Keshavan","year":"1994","journal-title":"Journal of Psychiatric Research"},{"issue":"2","key":"10.1002\/14651858.CD008661.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0113|cit113","doi-asserted-by":"crossref","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Metzendorf M Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook 10.1002\/9781119536604.ch4","DOI":"10.1002\/9781119536604.ch4"},{"issue":"1","key":"10.1002\/14651858.CD008661.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0149-7189(88)90033-X","article-title":"A quality of life interview for the chronically mentally ill","volume":"11","author":"Lehman","year":"1988","journal-title":"Evaluation and Program Planning"},{"issue":"11","key":"10.1002\/14651858.CD008661.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD008661.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD008661.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"2318-25","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0119|cit119","volume-title":"Neuropsychological Assessment","author":"Lezak","year":"1995"},{"issue":"5","key":"10.1002\/14651858.CD008661.pub2-BIB0120|cit120","first-page":"432","article-title":"Modafinil - the unique properties of a new stimulant","volume":"62","author":"Lyons","year":"1991","journal-title":"Aviation, Space, and Environmental Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008661.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4088\/JCP.v64n0420h","article-title":"Three case reports of modafinil use in treating sedation induced by antipsychotic medications","volume":"64","author":"Makela","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD008661.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00023210-199809040-00006","article-title":"Modafinil: a review of its pharmacology and clinical efficacy in the management of narcolepsy","volume":"9","author":"McClellan","year":"1988","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1002\/14651858.CD008661.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1741-7015-2-13","article-title":"A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology","volume":"2","author":"McGrath","year":"2004","journal-title":"BMC Medicine"},{"issue":"82","key":"10.1002\/14651858.CD008661.pub2-BIB0125|cit125","first-page":"1","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0126|cit126","unstructured":"Microsoft Excel Microsfot corporation 2016"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0127|cit127","unstructured":"Microsoft Word Microsfot corporation 2016"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0128|cit128","first-page":"327","article-title":"Pharmacokinetic profile of modafinil","volume":"32","author":"Moachon","year":"1996","journal-title":"Drugs of Today"},{"issue":"8","key":"10.1002\/14651858.CD008661.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1176\/appi.ajp.2008.07111713","article-title":"Relationship of cognition and psychopathology to functional impairment in schizophrenia","volume":"165","author":"Mohamed","year":"2008","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD008661.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/schbul\/12.3.408","article-title":"Attentional vulnerability indicators, thought disorder, and negative symptoms","volume":"12","author":"Nuechterlein","year":"1986","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD008661.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS Consensus Cognitive Battery, Part 1: Test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"10039","key":"10.1002\/14651858.CD008661.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/hup.456","article-title":"Modafinil affects mood, but not cognitive function, in healthy young volunteers","volume":"18","author":"Randall","year":"2003","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0135|cit135","first-page":"266","article-title":"Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers","volume":"5","author":"Robbins","year":"1994","journal-title":"Dementia"},{"issue":"1","key":"10.1002\/14651858.CD008661.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00002826-200401000-00011","article-title":"Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia","volume":"27","author":"Rosenthal","year":"2004","journal-title":"Clinical Neuropharmacology"},{"issue":"22","key":"10.1002\/14651858.CD008661.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.1523\/JNEUROSCI.20-22-08620.2000","article-title":"Hypothalamic arousal regions are activated during modafinil-induced wakefulness","volume":"20","author":"Scammell","year":"2000","journal-title":"Journal of Neuroscience"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0138|cit138","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.neuropharm.2012.07.011","article-title":"Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain","volume":"64","author":"Scoriels","year":"2013","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1002\/14651858.CD008661.pub2-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15171\/bi.2017.25","article-title":"Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis","volume":"7","author":"Shokraneh","year":"2017","journal-title":"BioImpacts"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13643-019-1035-3","article-title":"Study-based registers reduce waste in systematic reviewing: discussion and case report","volume":"8","author":"Shokraneh","year":"2019","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"Suppl 212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0143|cit143","unstructured":"Sterne JAC Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"10","key":"10.1002\/14651858.CD008661.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.biopsych.2004.02.008","article-title":"Modafinil improves cognition and response inhibition in adult attention-deficit\/hyperactivity disorder","volume":"55","author":"Turner","year":"2004","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008661.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/sj.npp.1300457","article-title":"Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia","volume":"29","author":"Turner","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD008661.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"30","key":"10.1002\/14651858.CD008661.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"12554","DOI":"10.1073\/pnas.0705087104","article-title":"Modafinil enhances thalamocortical activity by increasing neuronal electrotonic coupling","volume":"104","author":"Urbano","year":"2007","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"9995","key":"10.1002\/14651858.CD008661.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Vos","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD008661.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/00912709922007534","article-title":"A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers","volume":"39","author":"Wong","year":"1999","journal-title":"Journal of Clinical Pharmacology"},{"issue":"7","key":"10.1002\/14651858.CD008661.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008661.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:24:24Z","timestamp":1695493464000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008661.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":152,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008661.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,12]]}}}